CA-PTW
4.2.2020 18:02:10 CET | Business Wire | Press release
PTW , the industry-leading video games and tech services outsourcer, today announced the appointment of Kasturi Rangan and Andy Emery to their C-Suite.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005364/en/
Andy Emery has been with PTW for five years and is stepping into the role of Chief Operating Officer. Andy joined PTW in 2015 through the acquisition of his company SIDE, which transformed PTW’s audio line of business. In 1997, Andy founded SIDE in London along with Phil Evans and Steve Parker with the mission of bringing world class voice performances to video game productions. SIDE found great success in that mission, working on many of the industries’ best loved franchises and being recognized with ten Industry Excellence Awards along the way. SIDE was acquired by PTW in 2015 and Andy became an integral part of the PTW executive team. Initially, Andy oversaw the opening of two new SIDE locations, in Los Angeles and Shanghai and became Vice President of Strategy and Innovation. His most recent role included managing the entire European region as President of Europe for PTW.
“PTW is thrilled to have Andy as a part of our executive team,” said Deborah Kirkham, CEO of PTW. “Andy is immensely creative and is also a force for reason in a complex, and often disorderly, global business landscape. His broad industry and entrepreneurial experience is particularly unique, and we benefit from his vision and depth of expertise daily. We’re honored to welcome him to the C-Suite and look forward to his continued contributions to PTW.”
Kasturi Rangan joins Andy in his appointment to the C-Suite, advancing to the role of Chief Product Officer. Rangan has been an integral part of PTW for nearly a decade, significantly growing and leading operations across the Quality Assurance, Innovation, and the Customer Experience line of business. In his most recent role at PTW, Rangan was the Regional President, leading the North American and India operations. He was also recently appointed as the CEO of PTW’s new game and product development brand, Orange Rock Studios. In his role as CPO of PTW, Rangan will oversee the product innovation and transformation arm for PTW globally.
“The best CPOs are visionaries of the future and evangelists for great product; Rangan is both. Rangan is the voice of innovation and a power for disruption at PTW; he is the natural choice as our CPO, and I welcome Rangan to the C-Suite,” said Deborah Kirkham.
Kirkham concluded, “With these two new appointments, PTW is now poised to move into a bright and successful future. Rangan and Andy bring very different and necessary voices to our team of leaders and we are already working together to build the future of PTW and the future of gaming.”
About PTW*
PTW is a leading games, digital entertainment and interactive media solutions provider with 16 offices in 10 countries worldwide. Our range of services include quality assurance, localization, customer experience, engineering and development services, and audio production services. PTW brings 25 years’ experience and the infrastructure to create customized support for projects and clients of all sizes.
PTW, comprised of global subsidiaries, is a UK-based holding company formed in 2016 under the umbrella of Poletowin Pitcrew Holdings, Inc. which is listed on the 1st Section of Tokyo Stock Exchange as 3657. POLE TO WIN is a registered trademark of Pole To Win Co., Ltd. in Japan and other countries. All rights reserved. For more information, visit https://www.ptw.com/
*Pole To Win International is now “PTW”
Stay connected with PTW on Facebook , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005364/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom